{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:02:00Z","timestamp":1768870920385,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T00:00:00Z","timestamp":1368403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2050-6511-14-26","type":"journal-article","created":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T04:14:03Z","timestamp":1368418443000},"source":"Crossref","is-referenced-by-count":38,"title":["First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus"],"prefix":"10.1186","volume":"14","author":[{"given":"Anita","family":"Kapur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"O\u2019Connor-Semmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth K","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Hompesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn A","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W","family":"Polli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D","family":"James Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imao","family":"Mikoshiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,13]]},"reference":[{"key":"145_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589.","journal-title":"N Engl J Med"},{"key":"145_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865.","journal-title":"Lancet"},{"key":"145_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00592-009-0134-3","volume":"46","author":"D Giugliano","year":"2009","unstructured":"Giugliano D, Standl E, Vilsboll T, Betteridge J, Bonadonna R, Campbell I, Schernthaner G, Staels B, Trichopoulou A, Farinaro E: Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetol. 2009, 46: 173-181.","journal-title":"Acta Diabetol"},{"key":"145_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA: The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994, 93: 397-404.","journal-title":"J Clin Invest"},{"key":"145_CR5","first-page":"F459","volume":"263","author":"RG Wells","year":"1992","unstructured":"Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA: Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992, 263: F459-F465.","journal-title":"Am J Physiol"},{"key":"145_CR6","doi-asserted-by":"publisher","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","volume":"270","author":"G You","year":"1995","unstructured":"You G, Lee WS, Barros EJ, Kanai Y, Huo T, Khawaja S, Wells R, Nigam S, Hediger M: Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem. 1995, 270: 29365-29371.","journal-title":"J Biol Chem"},{"key":"145_CR7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ki.2009.87","volume":"75","author":"GL Bakris","year":"2009","unstructured":"Bakris GL, Fonseca VA, Sharma K, Wright EM: Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009, 75: 1272-1277.","journal-title":"Kidney Int"},{"key":"145_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2133\/dmpk.20.452","volume":"20","author":"M Nishimura","year":"2005","unstructured":"Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005, 20: 452-477.","journal-title":"Drug Metab Pharmacokinet"},{"key":"145_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","volume":"11","author":"I Idris","year":"2009","unstructured":"Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009, 11: 79-88.","journal-title":"Diabetes Obes Metab"},{"key":"145_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","volume":"447","author":"EM Wright","year":"2004","unstructured":"Wright EM, Turk E: The sodium\/glucose cotransport family SLC5. Pflugers Arch. 2004, 447: 510-518.","journal-title":"Pflugers Arch"},{"key":"145_CR11","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","volume":"14","author":"R Santer","year":"2003","unstructured":"Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich J, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift P, Schaub J, Klaerke D: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003, 14: 2873-2882.","journal-title":"J Am Soc Nephrol"},{"key":"145_CR12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1517\/13543776.15.11.1531","volume":"13","author":"AL Handlon","year":"2005","unstructured":"Handlon AL: Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat. 2005, 13: 1531-1540.","journal-title":"Expert Opin Ther Pat"},{"key":"145_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/0091270009351879","volume":"50","author":"E Hussey","year":"2010","unstructured":"Hussey E, Clark R, Amin D, Kipnes M, O\u2019Connor-Semmes R, O\u2019Driscoll E, Leong L, Murray S, Dobbins R, Layko D, Nunez D: The single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2010, 50: 623-635.","journal-title":"J Clin Pharmacol"},{"key":"145_CR14","first-page":"285","volume":"8","author":"M Isaji","year":"2007","unstructured":"Isaji M: Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs. 2007, 8: 285-292.","journal-title":"Curr Opin Investig Drugs"},{"key":"145_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009, 85: 513-519.","journal-title":"Clin Pharmacol Ther"},{"key":"145_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M: Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009, 85: 520-526.","journal-title":"Clin Pharmacol Ther"},{"key":"145_CR17","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.2174\/0929867043364360","volume":"11","author":"T Asano","year":"2004","unstructured":"Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y: Glucose transporter and Na+\/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem. 2004, 11: 2717-2724.","journal-title":"Curr Med Chem"},{"key":"145_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JR Ehrenkranz","year":"2005","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev. 2005, 21: 31-38.","journal-title":"Diabetes Metab Res Rev"},{"key":"145_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.106.110296","volume":"320","author":"K Katsuno","year":"2007","unstructured":"Katsuno K, Fujimori Y, Takemura Y: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007, 320: 323-330.","journal-title":"J Pharmacol Exp Ther"},{"key":"145_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Y Fujimori","year":"2008","unstructured":"Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M: Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008, 327: 268-276.","journal-title":"J Pharmacol Exp Ther"},{"key":"145_CR21","first-page":"529-P","volume":"58","author":"WW Harrington","year":"2008","unstructured":"Harrington WW, Milliken NO, Binz JG: Remogliflozin etabonate, a potent and selective sodium-dependent glucose transporter 2 antagonist, produced sustained metabolic effects in zucker diabetic fatty rats. Diabetes. 2008, 58: 529-P-","journal-title":"Diabetes"},{"key":"145_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/CBB:36:2-3:115","volume":"36","author":"EM Wright","year":"2002","unstructured":"Wright EM, Turk E, Martin MG: Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys. 2002, 36: 115-121.","journal-title":"Cell Biochem Biophys"},{"key":"145_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/dmd.112.047258","volume":"40","author":"J Sigafoos","year":"2012","unstructured":"Sigafoos J, Bowers G, Castellino S, Culp AG, Wagner DS, Reese JM, Humphreys JE, Hussey EK, O\u2019Connor-Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW: Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos. 2012, 40: 1-13.","journal-title":"Drug Metab Dispos"},{"key":"145_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.2040-1124.2011.00141.x","volume":"3","author":"D Yabe","year":"2012","unstructured":"Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, Sugizaki K, Fujiwara S, Hishizawa M, Hyo T, Kuwabara K, Yokota K, Iwasaki M, Kitatani N, Kurose T, Inagaki N, Seino Y: Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012, 3: 70-79. 10.1111\/j.2040-1124.2011.00141.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"145_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.beem.2009.03.006","volume":"23","author":"CF Deacon","year":"2009","unstructured":"Deacon CF, Holst JJ, Sugawara K: Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009, 23 (4): 425-462. ISSN 1521-690X, 10.1016\/j.beem.2009.03.006. [\n                    http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1521690X09000256\n                    \n                  ]","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2132-PO","key":"145_CR26","first-page":"A589","volume":"57","author":"R O\u2019Connor-Semmes","year":"2008","unstructured":"O\u2019Connor-Semmes R, Hussey EK, Dobbins RL, Nunez DJ: Simulation and prediction of long-term clinical efficacy in type 2 diabetes resulting from inhibition of the renal sodium-glucose cotransporter 2 (SGLT2). Diabetes. 2008, 57 (2132-PO): A589-","journal-title":"Diabetes"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-14-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T22:47:22Z","timestamp":1548110842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-14-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,13]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-14-26","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,13]]},"article-number":"26"}}